Informace o projektu
NGS-PTL - Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia
(NGS-PTL)
- Kód projektu
- 306242
- Období řešení
- 11/2012 - 10/2015
- Investor / Programový rámec / typ projektu
-
Evropská unie
- 7. rámcový program EU
- Spolupráce
- Fakulta / Pracoviště MU
- Středoevropský technologický institut
- Spolupracující organizace
-
Katholieke Universiteit Leuven
Universität Ulm
Universita di Bologna
- Odpovědná osoba prof. Giovanni Martinelli
Hematological diseases are highly heterogeneous malignancies in the matter of the molecular mechanisms related to their development and progression. A considerable heterogeneity can be further observed within the same hematological disease at the inter-individual level, being reflected by different clinical outcomes and responses to treatment in different patients. Nowadays the advent of high-throughput sequencing (HTS) technologies that are revolutionizing genomics and transcriptomics by providing a single base resolution tool for a unified deep analysis of diseases complexity allows a fast and cost-efficient fine-scale assessment of the genetic/genomic variability hidden within cohorts of patients affected by the same leukemia. That being so, by potentially highlighting inter-individual differences that may play a role in the differential success of diverse therapeutic interventions, they promise to be crucial for selecting the most appropriate medical treatments. This project aims at developing a European Hematological/HTS platform of scientists for improving outcomes for therapeutic interventions on acute and chronic leukemias and at develop strategies to personalize treatments and tailor therapies to different stratified groups of leukemia patients, with the goal of optimizing their efficacy and safety through a deeper and deeper understanding of the influence of genetic/genomic alterations on leukemias pathogenesis and treatment response (i.e. “personalized therapy”). Moreover, the final aim will be the identification of novel prognostic biomarkers for acute and chronic leukemias, as well as of molecular biomarkers and/or genomic profiles for the assessment of minimal residual disease. The originality of this project is to perform systematic deep genomic/transcriptomic studies on well-clinically-characterized leukemia patients, by exploiting HTS technologies able to quickly produce data with a good cost-effectiveness and an unprecedented resolution.
Publikace
Počet publikací: 18
2015
-
Mutations in the TP53 gene show features of somatic hypermutation process with prominent difference between IGHV mutated and unmutated chronic lymphocytic leukemia
Rok: 2015, druh: Konferenční abstrakty
-
Separation of residual malignant cells from peripheral blood of treated patients with chronic lymphocytic leukemia
Rok: 2015, druh: Konferenční abstrakty
-
The effect of ZAP-70 on adaptor molecule involved in microenvironmental interactions of malignant B cells
Rok: 2015, druh: Konferenční abstrakty
2014
-
Analysis of merkel cell polyomavirus prognostic significance in chronic lymphocytic leukemia
Rok: 2014, druh: Konferenční abstrakty
-
Biological and clinical relevance of mirnas induced in chronic lymphocytic leukemia (CLL) cells during administration of therapy in vivo and in vitro
Rok: 2014, druh: Konferenční abstrakty
-
Deep sequencing for detailed analysis of TP53 mutations clonal evolution in chronic lymphocytic leukemia
Rok: 2014, druh: Konferenční abstrakty
-
Deep sequencing for identification of minor-clone TP53 mutations before their clonal selection by therapy in chronic lmyphocytic leukemia
Rok: 2014, druh: Konferenční abstrakty
-
Hepcidin levels in Diamond-Blackfan anemia reflect erythropoietic activity and transfusion dependency
Haematologica, rok: 2014, ročník: 99, vydání: 7, DOI